|Day Low/High||231.54 / 236.56|
|52 Wk Low/High||208.07 / 287.94|
Two items are forcing the marketplace to take note as the morning unfolds. One, We already know that the Trump administration has long opposed the Affordable Care Act. The president has at least been smart enough to insinuate that the GOP not take t...
It becomes difficult to own for anything other than a trade, managed care stocks and those that most benefit from Medicare expansion.
I think sometimes the best way to parse the temperament is to go over the most obviously 'wrong' moves and address why they might not be wrong at all.
National security is job one. Cutting a nice deal with China that benefits both sides must come second.
If we didn't know where the algorithms that now control the point of sale were lined up before Monday, we sure know now.
Let's see what we can glean from the charts and indicators.
Pharmacy Benefit Managers (PBMs) are in for some problems if proposed regulation is given approval.
Healthcare is attracting some very healthy competition among mega-cap names.
Netflix has been underpricing its product in order to hook subscribers on its terrific content.
I continue to have a very difficult time finding individual stocks that I want to buy at this juncture.
Do we have to run for the hills? Not necessarily.
Has the sun set on what was the greatest wealth creator of any company when the stock traded north of a trillion dollars? No.
Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.
Use it to your advantage or don't use it at all.
Now for those of you haven't voted, please go and do so and don't vote this stuff just invest in it!
This name has significantly outperformed both the S&P 500 and the health care sector over the course of this awful month
It becomes difficult for me to tell you where to run in these markets...
Let's review the charts and indicators of this health care leader.
When looking at UNH stock, you're looking at reliability.
This is what the market looks like when the Fed says nothing and the president isn't ranting about something.
Adobe released new guidance for the rest of this year and 2019. With 20% growth in the cards, this name is a buy.
Straying from these names could land you in quicksand as the 4th quarter begins.
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
It is all about perception, and here are strong names to pick up on market weakness.
Sometimes you gotta have faith, but you also have to be a little more skeptical.
Activist investor Carl Icahn slammed Cigna's move to acquire Express Scripts.
Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.
Keep an eye on these business stories as stocks point lower on trade concerns.
The relentless emphasis on the FANG four has spawned the 'Dumas effect,' as ETFs force these stocks to trade together.